In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.06.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Jianji Ke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130021…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hydrogels, Liver Neoplasms, Nanoparticles. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a prevalent malignancy characterized by an exceedingly high recurrence rate post-surgery, significantly impairing the prognosis of HCC patients. However, a standard in-care strategy for postoperative therapy is still lacking. Although encouraging results have been obtained in a newly published clinical trial for postoperative therapy by targeting the vascular endothelial growth factor (VEGF) and programmed death ligand 1 (anti-PD-L1), its efficacy remains constrained. Combining a hemostatic hydrogel with a nanoparticle-based drug delivery system presents an opportunity to optimize the antitumor effect. Herein, we developed a nanoplatform, termed HMSN@Sor/aP@Gel, comprising a hemostatic fibrin hydrogel and functionalized hollow mesoporous silica nanoparticles (HMSNs) loaded with sorafenib and anti-PD-L1 for locally administered targeted-immunotherapy to prevent the postoperative recurrence and metastasis of HCC. The antitumor mechanism is grounded in dual inhibition of Ras/Raf/MEK/ERK (MAPK) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathways, synergistically complemented by PD-L1 blockade. HMSN@Sor/aP@Gel facilitates dendritic cell maturation, enhances cytotoxic T-lymphocyte infiltration, promotes the polarization of tumor-associated macrophages to M1 phenotype, induces tumor immunogenic cell death, reverses immunosuppression, and establishes immune memory to counter postoperative recurrence. Animal studies corroborate that HMSN@Sor/aP@Gel-mediated targeted immunotherapy significantly impedes primary and metastatic tumor growth and establishes immune memory to prevent recurrence post-surgery. This investigation presents a promising strategy for postoperative therapy with considerable potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130021, China.
- Department of Critical Care Medicine, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130021, China.
- Department of Colorectal and Anal Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130021, China.
- State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun 130012, China.
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130021, China. Electronic address: ji_bai@jlu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ke, J., Liu, Y., Liu, F., Cai, H., Li, X., Zhang, Z., Wang, N., Shao, B., Wang, Z., Han, M., & Ji, B. (2024). In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.06.030
Vancouver
Ke J, Liu Y, Liu F, Cai H, Li X, Zhang Z, et al. In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.06.030
BibTeX
@article{Ke2024,
author = {Ke, Jianji and Liu, Yahui and Liu, Feiqi and Cai, Hongqiao and Li, Xiaocheng and Zhang, Zhiyuan and Wang, Ning and Shao, Bingru and Wang, Zhihua and Han, Mingda and Ji, Bai},
title = {In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.06.030}
}
EUVIMED